[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564943":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":30,"id":34,"slug":19,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":19,"eligibilityCriteria":39,"healthyVolunteers":40,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":19,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":55,"whyStopped":19,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":19},{"fullName":5,"class":6},"Stanford University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Vinpocetine","EXPERIMENTAL","Participants will take increasing, single doses of vinpocetine.",[13],"Drug: Vinpocetine",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Increasing doses of vinpocetine to assess tolerability.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Jordan Seliger","CONTACT","650-460-9260","jseliger@stanford.edu",{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Kimford Jay Meador","Professor of Neurology",[31],{"name":32,"class":33},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","NIH","100564943",false,"NCT06635746","Dose Escalation Study of Vinpocetine in Healthy Volunteers","Phase I, Open Label, Dose-Escalation Study for Maximum Tolerated Vinpocetine Dose in Healthy Volunteers","Inclusion Criteria:\n\n1. Healthy adults 18-40 years old.\n2. Proficient English.\n3. Use of appropriate contraception if woman of childbearing potential.\n\nExclusion Criteria:\n\n1. Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression).\n2. Those who score \\>18 overall on the BDI-II or \\>0 for item #9 (suicidal thoughts) at screening.\n3. Use of centrally active medications.\n4. History of allergy to vinpocetine.\n5. IQ\\\u003C80.\n6. BMI≥30.\n7. Pregnancy or lactation.",true,"ALL","18 Years","40 Years",{"count":45,"type":46},20,"ESTIMATED","INTERVENTIONAL",[49],"PHASE1","The objective of this study is to determine whether vinpocetine is safe when taken at higher doses.",[52],"Fetal Alcohol Spectrum Disorders",[54,9],"Cognition","NOT_YET_RECRUITING","2024-10-08",{"date":58,"type":59},"2024-10-10","ACTUAL",{"date":61,"type":46},"2025-06-01",{"date":63,"type":46},"2026-06-01",{"name":5,"class":6}]